Management and Treatment of Patients With Exon 20 Non–Small Cell Lung Cancer
This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.
Latest Recommendations for Broad Molecular Testing in Advanced NSCLC
September 14th 2022During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion
October 19th 2022During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.
Choosing Early-Line Therapy for NSCLC With an EGFR Exon 20 Insertion
November 16th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC
December 5th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.
